Home / Health / New Device Delivers Chemo Locally
New Device Delivers Chemo Locally
10 Aug
Summary
- RenovoCath device used for sarcoma treatment.
- Chemotherapy delivered directly near tumor.
- Potential to reduce toxicity compared to IV.
RenovoRx has announced the initial commercial use of its RenovoCath device for treating a sarcoma patient at the CARTI Cancer Center in Arkansas, USA. This procedure marks a significant expansion, as the device, previously used for pancreatic cancer, has now been applied to target solid tumors like sarcoma.
The RenovoCath device allows clinicians to administer chemotherapy directly to the tumor area. This localized delivery aims to offer a more targeted approach compared to systemic intravenous chemotherapy, potentially reducing toxicity for patients.
Sarcoma, a cancer of soft tissues or bones, presents treatment challenges due to its variable location and often lower responsiveness to standard chemotherapy. CARTI clinicians chose RenovoCath, having seen its benefits in localizing treatment for pancreatic cancer.
The device received US Food and Drug Administration clearance for isolating blood flow and delivering agents to specific sites in the peripheral vascular system. RenovoRx began commercializing RenovoCath in December 2024, following initial purchase orders.
